Document:

EX-10.2

 Exhibit 10.2 

SETTLEMENT AGREEMENT 
 This
Settlement Agreement (“Agreement”) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General
(“OIG-HHS”) of the Department of Health and Human Services (“HHS”) (collectively, the “United States”), Mallinckrodt plc and Mallinckrodt ARD LLC (f/k/a Questcor Pharmaceuticals,
Inc.), debtors and debtors-in-possession acting on behalf of themselves and their estates (collectively, “Mallinckrodt”)1, and Charles Strunck, Lisa Pratta, and Scott Clark (each a “Relator” and, collectively, the “Relators”) (hereafter collectively referred to as “the Parties”), through
their authorized representatives. 
 RECITALS 

A. When a patient obtains a prescription drug covered by Medicare, the patient may be required to make a payment, which may take the form of a
“copayment,” “coinsurance,” or “deductible” (collectively “co-pays”). The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b,
prohibits pharmaceutical companies from paying remuneration – which includes money or any other item of value (such as a co-pay) – to induce Medicare beneficiaries to purchase, or their physicians to
prescribe, the companies’ drugs that are reimbursed by Medicare. 
 B. Mallinckrodt plc is an Irish public limited company. Its
subsidiary, Mallinckrodt ARD, LLC (f/k/a Questcor Pharmaceuticals, Inc.), is a California limited liability company with its principal place of business in New Jersey. Mallinckrodt does business as a pharmaceutical manufacturer in the United States
and markets H.P. Acthar Gel (“Acthar”) in the United States. 
  

 

	1	 References to Mallinckrodt shall include and encompass any reorganized Mallinckrodt created by the Approved
Plan (defined herein) confirmed by the Bankruptcy Court. For the avoidance of doubt: (a) reorganized Mallinckrodt plc and reorganized Mallinckrodt ARD LLC shall be considered successors to Mallinckrodt plc and Mallinckrodt ARD LLC,
respectively, and be fully responsible for any liabilities, obligations, or conditions included in this Settlement Agreement; (b) the Approved Plan shall provide for (i) the reorganization and continued corporate existence of Mallinckrodt
plc and Mallinckrodt ARD LLC and (ii) the vesting of the assets of Mallinckrodt plc and Mallinckrodt ARD LLC in reorganized Mallinckrodt plc and Mallinckrodt ARD LLC upon the effective date of the confirmed Approved Plan. 

 C. On January 20, 2012, Charles Strunck and Lisa Pratta filed an action in the United
States District Court for the Eastern District of Pennsylvania captioned United States ex rel. Strunck v. Questcor Pharmaceuticals, Inc., Civil Action No. 12-175 (BMS), pursuant to the qui
tam provisions of the False Claims Act, 31 U.S.C. § 3730(b) (the “Strunck Action”). On June 12, 2017, the Court accepted for filing the Fourth Amended Complaint in the Strunck Action. 

D. On April 4, 2013, Scott Clark filed an action in the United States District Court for the Eastern District of Pennsylvania captioned
United States, et al., ex. rel. Clark v. Questcor Pharmaceuticals, Inc., Civil Action No. 13-cv-01776 (BMS), pursuant to the qui tam provisions of
the False Claims Act, 31 U.S.C. § 3730(b) (the “Clark Action”). 
 E. The Strunck and Clark Actions are collectively referred
to as the “Civil Actions.” The Civil Actions allege, inter alia, that Mallinckrodt provided illegal remuneration to Medicare patients in violation of the Anti-Kickback Statute, in the form of
co-pay subsidies for Acthar. 
 F. The United States intervened in the Civil Actions on March 6,
2019, and filed the United States’ Complaint-in-Intervention on June 4, 2019 (“United States’ Complaint-in-Intervention”). On September 3, 2019, the United States and Mallinckrodt ARD LLC entered into a civil False Claims Act settlement (“2019 FCA Agreement”) to resolve allegations
related to twelve Questcor sales representatives for the time period January 1, 2009 to December 31, 2013 (hereinafter, the “Resolved Acthar Claims”). By September 20, 2019, Mallinckrodt made the payment required under the
2019 FCA Agreement concerning the Resolved Acthar Claims and the parties filed a joint stipulation of dismissal and proposed order required by the 2019 FCA Agreement. The court entered the proposed order on September 24, 2019. 

G. The United States contends that it has certain civil claims against Mallinckrodt arising from conduct alleged in the United States’ Complaint-in-Intervention in the Civil Actions that were not resolved by the 2019 FCA Agreement. That conduct is referred to below as the “Covered Conduct.” 

  
 2 

 H. Relators claim entitlement under 31 U.S.C. § 3730(d) to a share of the proceeds of
this Agreement and to Relators’ reasonable expenses, attorneys’ fees and costs. 
 I. The Parties have negotiated this Agreement in
good faith and at arm’s length and intend the Agreement to be consummated through (a) the voluntary cases under chapter 11 of the Bankruptcy Code (as defined below) (the “Chapter 11 Cases”) filed in the United States
Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) Case No. 20-12522 (JTD), by Mallinckrodt ARD LLC and certain of its affiliates and subsidiaries on October 12, 2020,
(b) the examinership proceeding to be commenced by Mallinckrodt plc under the laws of Ireland (the “Examinership Proceeding”), and (c) the proceedings commenced under Part IV of the Canadian Companies Arrangement Act to recognize in
Canada the Chapter 11 Cases and to recognize in Canada certain orders of the Bankruptcy Court (the “Canadian Recognition Proceeding” and, collectively with the Chapter 11 Cases and the Examinership Proceeding, the “Bankruptcy
Proceedings”).2 
 J. This Agreement is neither an admission of liability by
Mallinckrodt nor a concession by the United States that its claims are not well founded. 
 In consideration of the mutual promises and
obligations of this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree and covenant as follows: 

 
  

	2	 Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in Exhibit A.

  
 3 

 TERMS AND CONDITIONS 

1. Mallinckrodt shall pay to the United States $26,292,134.82, plus interest accruing at an annual rate of 0.6255%, running from
September 21, 2020, in eight installments, pursuant to the installment payment schedule described in Exhibit B (the “Settlement Amount”), by electronic funds transfer pursuant to written instructions to be provided by the United
States Attorney’s Office for the Eastern District of Pennsylvania. The interest described in the foregoing sentence shall accrue on the outstanding balance of the remaining installment payments and all then-accrued interest shall be payable in
cash to the United States contemporaneously with each installment payment as set forth on Exhibit B. The entire Settlement Amount shall be considered restitution. The entire balance of the Settlement Amount, or any portion thereof, may be prepaid
without premium or penalty. If Mallinckrodt elects to prepay the Settlement Amount, or any portion thereof, interest shall accrue through the date on which Mallinckrodt makes said prepayment. If Mallinckrodt is sold, merged, or transferred, or all
or substantially all of the assets of Mallinckrodt (on a consolidated basis) are sold, merged, or transferred into another non-affiliated entity, Mallinckrodt shall promptly notify the United States, and all
remaining payments owed pursuant to the Settlement Agreement shall be accelerated and become immediately due and payable upon consummation of such transaction. 

2. Conditioned upon the United States receiving the Settlement Amount installment payments from Mallinckrodt, the United States agrees that it
shall pay by electronic funds transfer to Relators Strunck and Pratta (collectively) nineteen (19) % of each such payment received under the Agreement (“Relator’s Share”) as soon as feasible after receipt of the payment. 

  
 4 

 3. Mallinckrodt has agreed to pay Relators’ Strunck and Pratta’s reasonable
expenses, attorneys’ fees and costs, as contemplated by 31 U.S.C. § 3730(d) and comparable provisions of any applicable state statutes and will do so subject to terms set forth in a separate agreement that Mallinckrodt and Relators Strunck
and Pratta will enter into contemporaneously with this agreement. 
 4. Subject to the exceptions in Paragraph 7 (concerning reserved claims)
below, and subject to Paragraph 10 (concerning disclosure of assets), and subject to Paragraphs 19 and 20, below (concerning bankruptcy), and upon the United States’ receipt of the Settlement Amount, the United States releases Mallinckrodt,
together with its current or former parent corporations; subsidiaries; brother or sister corporations; divisions; current or former corporate owners; and the corporate successors and assigns of any of them (the “Mallinckrodt Releasees”),
from any civil or administrative monetary claim the United States has for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-33, the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a, the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-12, any statutory provision for which the Civil Division of the Department of Justice has actual
and present authority to assert and compromise pursuant to 28 CFR Part 0; Subpart I, 0.45(d); or the common law theories of payment by mistake, unjust enrichment, and fraud. 

5. Subject to the exceptions in Paragraph 7 (concerning reserved claims) below, and subject to Paragraph 10 (concerning disclosure of assets)
and subject to Paragraphs 19 and 20, below (concerning bankruptcy), and upon the United States’ receipt of the Settlement Amount, Relators, for themselves and for their heirs, successors, attorneys, agents, and assigns, release the Mallinckrodt
Releasees from any civil monetary claim the Relators have on behalf of the United States for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-33. 

  
 5 

 6. In consideration of the obligations of Mallinckrodt in this Agreement and the Corporate
Integrity Agreement (CIA), entered into between OIG-HHS and Mallinckrodt plc and upon the United States’ receipt of full payment of the Settlement Amount, plus interest due under Paragraph 1, the OIG-HHS shall release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C.
§ 1320a-7b(f)) against Mallinckrodt under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. §
1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in this paragraph and in Paragraph 7 (concerning reserved claims), below.
The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude Mallinckrodt from Medicare, Medicaid, and other Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct
and practices, for which claims have been reserved in Paragraph 7, below. 
 7. Notwithstanding the releases given in paragraphs 4 and 6 of
this Agreement, or any other term of this Agreement, the following claims of the United States are specifically reserved and are not released: 
  

	 	a.	 Any liability arising under Title 26, U.S. Code (Internal Revenue Code); 

 

	 	b.	 Any criminal liability; 

 

	 	c.	 Except as explicitly stated in this Agreement, any administrative liability or enforcement right, including
mandatory exclusion from Federal health care programs; 

  

	 	d.	 Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;

  

	 	e.	 Any liability based upon obligations created by this Agreement; and 

 

	 	f.	 Any liability of individuals. 

  
 6 

 8. Relators and their heirs, successors, attorneys, agents, and assigns shall not object to
this Agreement but agree and confirm that this Agreement is fair, adequate, and reasonable under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B). Conditioned upon Relator Strunck and Pratta’s receipt of Relator’s Share,
Relators and their heirs, successors, attorneys, agents, and assigns fully and finally release, waive, and forever discharge the United States, its agencies, officers, agents, employees, and servants, from any claims arising from the filing of the
Civil Actions or under 31 U.S.C. § 3730, and from any claims to a share of the proceeds of this Agreement and/or the Civil Actions. 

9. Relators, for themselves, and for their heirs, successors, attorneys, agents, and assigns, fully and finally release the Mallinckrodt
Releasees, and their officers, agents, and employees, from any liability (including attorneys’ fees, costs, and expenses of every kind and however denominated, outside of those contemplated in a separate agreement that Mallinckrodt and Relators
Strunck and Pratta will enter into contemporaneously with this agreement) that Relators have asserted, could have asserted, or may assert in the future against Mallinckrodt related to the Civil Actions or the Covered Conduct and Relators’
investigation or prosecution thereof, or any liability to Relators arising from the filing of the Civil Actions, or under 31 U.S.C. § 3730(d) for expenses or attorneys’ fees and costs. Notwithstanding the foregoing, this release does not
include Relator Clark’s separate claims against Mallinckrodt for retaliation in violation of 31 U.S.C. § 3730(h) and Oregon law, currently pending in the Chapter 11 Cases. 

  
 7 

 10. Mallinckrodt has provided sworn financial disclosures and supporting documents
(“Financial Disclosures”) to the United States, and the United States has relied on the accuracy and completeness of those Financial Disclosures in reaching this Agreement. Mallinckrodt warrants that the Financial Disclosures are complete,
accurate, and current as of the date provided. If the United States learns of asset(s) in which Mallinckrodt had an interest of any kind as of the Effective Date of this Agreement (including, but not limited to, promises by insurers or other third
parties to satisfy Mallinckrodt’s obligations under this Agreement) that were not disclosed in the Financial Disclosures, or if the United States learns of any false statement or misrepresentation by Mallinckrodt on, or in connection
with, the Financial Disclosures, and if such nondisclosure, false statement or misrepresentation changes the estimated net worth set forth in the Financial Disclosures by $12.5 million or more, the United States may at its option:
(a) rescind this Agreement and reinstate its suit or file suit based on the Covered Conduct in the United States District Court for the Eastern District of Pennsylvania, or (b) collect the full Settlement Amount in accordance with the Agreement
plus one hundred percent (100%) of the net value of Mallinckrodt’s previously undisclosed assets. Mallinckrodt agrees not to contest any collection action undertaken by the United States pursuant to this provision, and agrees that it will
immediately pay the United States (i) a ten-percent (10%) surcharge of the amount collected in the collection action, or (ii) the United States reasonable attorneys’ fees and expenses incurred
in such an action, in each case, to the extent allowed by 28 U.S.C. § 3011. 
 In the event that the United States, pursuant to this
paragraph, rescinds this Agreement, Mallinckrodt waives and agrees not to plead, argue, or otherwise raise any defenses under the theories of statute of limitations, laches, estoppel, or similar theories, including theories related to the Bankruptcy
Proceedings such as discharge, to any civil or administrative claims that (a) are filed by the United States within 120 calendar days of written notification to Mallinckrodt that this Agreement has been rescinded, and (b) relate to the
Covered Conduct, except to the extent these defenses were available on January 20, 2012. 

  
 8 

 11. Mallinckrodt waives and shall not assert any defenses Mallinckrodt may have to any
criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines
Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action. 

12. Mallinckrodt fully and finally releases the United States, its agencies, officers, agents, employees, and servants, from any claims
(including for attorneys’ fees, costs, and expenses of every kind and however denominated) that Mallinckrodt has asserted, could have asserted, or may assert in the future against the United States, its agencies, officers, agents, employees,
and servants, related to the Covered Conduct or the United States’ investigation or prosecution thereof. 
 13. Mallinckrodt fully and
finally releases the Relators and their respective heirs, successors, attorneys, agents, and assigns from any claims (including attorneys’ fees, costs, and expenses of every kind and however denominated) that Mallinckrodt has asserted, could
have asserted, or may assert in the future against Relators related to the Civil Actions or the Covered Conduct and Relators’ investigation or prosecution thereof. Notwithstanding the foregoing, this release does not include any claims
Mallinckrodt may have against Relator Clark relating to his separate claims against Mallinckrodt for retaliation in violation of 31 U.S.C. § 3730(h) and Oregon law, currently pending in the Chapter 11 Cases. 

14. The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any
Medicare contractor (e.g., Medicare Administrative Contractor, fiscal intermediary, carrier or any state payer) related to the Covered Conduct; and Mallinckrodt agrees not to resubmit to any Medicare contractor or any state payer any
previously denied claims related to the Covered Conduct, agrees not to appeal any such denials of claims, and agrees to withdraw any such pending appeals. 

  
 9 

 15. Mallinckrodt agrees to the following: 

a. Unallowable Costs Defined: All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395lll-1 and 1396-1396w-5; and the
regulations and official program directives promulgated thereunder) incurred by or on behalf of Mallinckrodt, its present or former officers, directors, employees, shareholders, and agents in connection with: 

 

	 	(1)	 the matters covered by this Agreement; 

 

	 	(2)	 the United States’ audits and investigations of the matters covered by this Agreement;

  

	 	(3)	 Mallinckrodt’s investigation, defense, and corrective actions undertaken in response to the United
States’ audits and investigations in connection with the matters covered by this Agreement (including attorneys’ fees); 

  

	 	(4)	 the negotiation and performance of this Agreement; 

 

	 	(5)	 the payment Mallinckrodt makes to the United States pursuant to this Agreement and any payments that
Mallinckrodt may make to Relators, including for costs and attorneys’ fees; and 

  

	 	(6)	 the negotiation of, and obligations undertaken pursuant to the CIA to: (i) retain an independent review
organization to perform annual reviews as described in Section III of the CIA; and (ii) prepare and submit reports to OIG-HHS, 

  
 10 

 are unallowable costs for government contracting purposes and under the Medicare Program, Medicaid Program,
TRICARE Program, and Federal Employees Health Benefits Program (FEHBP) (hereinafter referred to as Unallowable Costs). However, nothing in paragraph 15.a.6 that may apply to the obligations undertaken pursuant to the CIA affects the status of costs
that are not allowable based on any other authority applicable to Mallinckrodt. 
 b. Future Treatment of Unallowable Costs:
Unallowable Costs shall be separately determined and accounted for by Mallinckrodt, and Mallinckrodt shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek
payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Mallinckrodt or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs. 

c. Treatment of Unallowable Costs Previously Submitted for Payment: Mallinckrodt further agrees that within 120 days of the Effective
Date of this Agreement it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments
previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by Mallinckrodt or any of its
subsidiaries or affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the effect of the inclusion of the Unallowable Costs.
Mallinckrodt agrees that the United States, at a minimum, shall be entitled to recoup from Mallinckrodt any overpayment plus applicable interest and penalties as a result of the inclusion of such Unallowable Costs on previously-submitted cost
reports, information reports, cost statements, or requests for payment. 

  
 11 

 Any payments due after the adjustments have been made shall be paid to the United States
pursuant to the direction of the Department of Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by Mallinckrodt or any of its subsidiaries or affiliates on the effect of
inclusion of Unallowable Costs (as defined in this Paragraph) on Mallinckrodt or any of its subsidiaries or affiliates’ cost reports, cost statements, or information reports. 

d. Nothing in this Agreement shall constitute a waiver of the rights of the United States to audit, examine, or
re-examine Mallinckrodt’s books and records to determine that no Unallowable Costs have been claimed in accordance with the provisions of this Paragraph. 

16. Mallinckrodt agrees to cooperate fully and truthfully with the United States’ investigation of individuals and entities not released
in this Agreement. Upon reasonable notice, Mallinckrodt shall encourage, and agrees not to impair, the cooperation of its directors, officers, and employees, and shall use its best efforts to make available, and encourage, the cooperation of former
directors, officers, and employees for interviews and testimony, consistent with the rights and privileges of such individuals. Mallinckrodt further agrees to furnish to the United States, upon request, complete and unredacted copies of all non-privileged documents, reports, memoranda of interviews, and records in its possession, custody, or control concerning any investigation of the Covered Conduct that it has undertaken, or that has been performed
by another on its behalf. 
 17. This Agreement is intended to be for the benefit of the Parties only. The Parties do not release any claims
against any other person or entity, except to the extent provided for in Paragraph 18 (waiver for beneficiaries paragraph), below. 

  
 12 

 18. Mallinckrodt agrees that it waives and shall not seek payment for any of the health care
billings covered by this Agreement from any health care beneficiaries or their parents, sponsors, legally responsible individuals, or third party payors based upon the claims defined as Covered Conduct. 

19. The Settlement Amount represents the amount the United States is willing to accept in compromise of its civil claims arising from the
Covered Conduct due solely to Mallinckrodt’s financial condition as reflected in the Financial Statements referenced in Paragraph 10. 

a. In the event that Mallinckrodt fails to pay any portion of the Settlement Amount as provided in the payment schedule set forth in Paragraph
1 above, Mallinckrodt shall be in default of Mallinckrodt’s payment obligations (“Payment Default”). The United States will provide a written Notice of Payment Default, and Mallinckrodt shall have an opportunity to cure such Payment
Default within seven (7) business days from the date of receipt of the Notice of Payment Default by making the payment due under the payment schedule and paying any additional interest accruing under the Agreement up to the date of payment.
Notice of Payment Default will be delivered to Mallinckrodt, or to such other representative as Mallinckrodt shall designate in advance in writing. If Mallinckrodt fails to cure the Payment Default within seven (7) business days of receiving the
Notice of Payment Default and in the absence of an agreement with the United States to a modified payment schedule (“Uncured Payment Default”), the remaining unpaid balance of the Settlement Amount shall become immediately due and payable,
and interest on the remaining unpaid balance shall thereafter accrue at the rate of 12% per annum, compounded daily from the date of Payment Default, on the remaining unpaid total (principal and interest balance). 

  
 13 

 b. In the event of an Uncured Payment Default, Mallinckrodt agrees that the United States,
at its sole discretion, may (i) retain any payments previously made, rescind this Agreement and pursue the Civil Actions, except with respect to the Resolved Acthar Claims, reinstate the Complaint-in-Intervention or bring any civil and/or administrative claim, action, or proceeding against Mallinckrodt in the United States District Court for the Eastern District of Pennsylvania for the claims
that would otherwise be covered by the releases provided in Paragraphs 4 and 6 above, with any recovery reduced by the amount of any payments previously made by Mallinckrodt to the United States under this Agreement; (ii) take any action to
enforce this Agreement in a new action or by reinstating the Civil Actions, except with respect to the Resolved Acthar Claims; (iii) offset the remaining unpaid balance from any amounts due and owing to Mallinckrodt and/or affiliated companies
by any department, agency, or agent of the United States at the time of Payment Default or subsequently; and/or (iv) exercise any other right granted by law, or under the terms of this Agreement, or recognizable at common law or in equity. The
United States shall be entitled to any other rights granted by law or in equity by reason of Payment Default, including referral of this matter for private collection. In the event the United States pursues a collection action, Mallinckrodt agrees
immediately to pay the United States (i) a ten-percent (10%) surcharge of the amount collected in the collection action, or (ii) the United States reasonable attorneys’ fees and expenses
incurred in such an action, in each case, to the extent allowed by 28 U.S.C. § 3011. In the event that the United States opts to rescind this Agreement pursuant to this Paragraph, Mallinckrodt waives and agrees not to plead, argue, or otherwise
raise any defenses of statute of limitations, laches, estoppel or similar theories, including theories related to the Bankruptcy Proceedings such as discharge, to any civil or administrative claims that are (i) filed by the United States
against Mallinckrodt within 120 days of written notification that this Agreement has been rescinded, and (ii) relate to the Covered Conduct, except to the extent these defenses were available on January 20, 2012. Mallinckrodt agrees not to
contest any offset, recoupment, and /or collection action undertaken by the United States pursuant to this Paragraph, either administratively or in any state or federal court, except on the grounds of actual payment to the United States. 

  
 14 

 c. In the event of an Uncured Payment Default,
OIG-HHS may exclude Mallinckrodt from participating in all Federal health care programs until Mallinckrodt pays the Settlement Amount, with interest, and reasonable costs as set forth above (“Exclusion
for Default”). OIG-HHS will provide written notice of any such exclusion to Mallinckrodt. Mallinckrodt waives any further notice of the exclusion under 42 U.S.C. §
1320a-7(b)(7), and agrees not to contest such exclusion either administratively or in any state or federal court. Reinstatement to program participation is not automatic. If at the end of the period of
exclusion, Mallinckrodt wishes to apply for reinstatement, it must submit a written request for reinstatement to OIG-HHS in accordance with the provisions of 42 C.F.R. §§ 1001.3001-.3005.
Mallinckrodt will not be reinstated unless and until OIG-HHS approves such request for reinstatement. The option for Exclusion for Payment Default is in addition to, and not in lieu of, the options identified
in this Agreement or otherwise available. 
 20. In exchange for valuable consideration provided in this Agreement, Mallinckrodt agrees to
the following: 
 a. The Definitive Documents related to the Bankruptcy Proceedings shall be consistent in all material respects with this
Agreement and shall not in any manner, by their terms, contain any provisions that amend, modify, supplement, supersede or conflict with, any of the provisions of this Agreement in any manner that is materially adverse to, or materially prejudicial
to the United States, in each case, with respect to its rights under this Settlement Agreement. The Definitive Documents shall be in form and substance reasonably acceptable to the United States. In addition, Mallinckrodt shall take such actions as
may be reasonably necessary or appropriate in the Bankruptcy Proceedings (including, without limitation, assuming its obligations under this Agreement pursuant to the Approved Plan, the Canadian Recognition Proceeding, and the Scheme of Arrangement)
to ensure Mallinckrodt will be able to comply with its obligations under this Agreement. 

  
 15 

 b. Where the provisions of this Agreement refer or apply to the Chapter 11 Cases, the
Bankruptcy Court, and/or the Plan (including the Definitive Documents and any other documentation relating or relevant thereto) or events, circumstances, or procedures in the United States (the “US Process”) but do not equally reference or
apply to the Examinership Proceeding, the Irish court, the Canadian Recognition Proceeding, the Canadian court, and/or the Scheme of Arrangement (including the Definitive Documents or any other documentation relating or relevant thereto) or
equivalent events, circumstances, or procedures in Ireland or Canada (the “Foreign Processes”), those provisions relating to the US Process shall be deemed to apply or refer equally to the Foreign Processes (and, if necessary, this
Agreement will be deemed to include provisions relating to the Foreign Processes which correspond to provisions relating to the US Process) to ensure that the rights and obligations of the United States under this Agreement apply equally to the
Foreign Processes in the same way as the US Process, to the fullest extent necessary in order to implement the terms, spirit, and intent of this Agreement. Mallinckrodt shall (i) provide the United States with a copy of the Approved Plan or any
other plan or reorganization or liquidation for which it intends seek approval from the Bankruptcy Court no later than ten days prior to filing such plan with the Bankruptcy Court, and (ii) obtain approval of the Approved Plan from the United
States. The United States shall not withhold approval without a reasonable, good faith basis and will inform Mallinckrodt of the reasons for withholding approval, if any. Mallinckrodt shall have seven (7) days to revise the plan and seek
approval of the revised plan from the United States. 

  
 16 

 c. If the Chapter 11 Cases or the Irish Examinership of Mallinckrodt are converted or
dismissed, the United States shall have the right to rescind this agreement with the same protections, contemplated in paragraph 19.b., as though Mallinckrodt has committed a Payment Default. 

d. The United States may, in its sole discretion, declare that the occurrence of any of the following events is a default of
Mallinckrodt’s obligations under this Agreement (each “an Event of Default”): 
  

	 	i.	 the Plan Effective Date does not occur on or before June 30, 2022, or such later date to which the United
States may consent (such consent not to be unreasonably withheld); 

  

	 	ii.	 the Bankruptcy Court (or other court of competent jurisdiction) enters an order, (A) directing the
appointment of an examiner with expanded powers or a trustee in any of the Chapter 11 Cases, or (B) converting any of the Chapter 11 Cases to cases under chapter 7 of the Bankruptcy Code; 

 

	 	iii.	 the Bankruptcy Court (or other court of competent jurisdiction, including the Irish Court) enters an order, the
effect of which would render the Approved Plan incapable of consummation on the terms set forth in this Agreement. 

  

	 	iv.	 the Bankruptcy Court (or other court of competent jurisdiction, including the Irish court) grants relief that
is inconsistent with this Agreement; 

  
 17 

	 	v.	 issuance by the Bankruptcy Court or any other court of competent jurisdiction, including the Irish court, of
any ruling, judgment or order enjoining the consummation of this Agreement or the Approved Plan, or denying approval of this Agreement; 

  

	 	vi.	 (a) the filing of a pleading by Mallinckrodt seeking to withdraw, amend or modify the Approved Plan, any
of the Definitive Documents, or any motion to assume or approve this Agreement, which withdrawal, amendment, modification or filing is not consistent with this Agreement in any material respect, or (b) if Mallinckrodt, files any motion or
pleading that is not consistent with this Agreement in any material respect and such motion or pleading has not been withdrawn prior to the earlier of (i) three (3) business days after Mallinckrodt receives written notice from the United States
that such motion or pleading is inconsistent with this Agreement, and (ii) the entry of an order of a court approving such motion; 

  

	 	vii.	 the Bankruptcy Court enters an order denying confirmation of the Approved Plan; and 

 

	 	viii.	 any court of competent jurisdiction has entered a judgment or order declaring this Agreement to be
unenforceable. 

 An Event of Default may be waived by the written consent of the United States. 

  
 18 

 e. (1) If an Event of Default occurs and has not been waived by written consent of the
United States; or (2) if, before the Settlement Amount is paid in full, Mallinckrodt or a third party commences a case, proceeding, or other action under any law relating to bankruptcy, insolvency, reorganization, or relief of debtors seeking
any order for relief of Mallinckrodt’s debts, or to adjudicate Mallinckrodt as bankrupt or insolvent; or seeking appointment of a receiver, trustee, custodian, or other similar official for Mallinckrodt or for all or any substantial part of
Mallinckrodt’s assets (in each case, other than the Bankruptcy Proceedings contemplated by this Agreement) (collectively a “Future Insolvency Proceeding”) or if Mallinckrodt’s obligations under this Agreement are avoided for any
reason (including but not limited to, through the exercise of a trustee’s avoidance powers under the Bankruptcy Code) in a Future Insolvency Proceeding or in any other case, proceeding or action: 

 

	 	i.	 the United States, at its sole option, may rescind the releases in this Agreement and bring any civil and/or
administrative claim, action, or proceeding against Mallinckrodt for the claims that would otherwise be covered by the releases provided in Paragraphs 4 and 6 above, including but not limited to, by re-filing
the Complaint-in-Intervention in the United States District Court for the Eastern District of Pennsylvania; provided, that any such claims shall be reduced by the
amount of any payments received pursuant to this Agreement; 

  

	 	ii.	 in any Future Insolvency Proceeding in which this Agreement is not assumed and the Settlement Amount is not
otherwise paid in full, the United States shall be entitled to, at its option an undisputed, noncontingent, and liquidated claim that is not subject to reconsideration or subordination against Mallinckrodt for either: (A) the then-unpaid balance of
the Settlement Amount, or (B) single damages of $72 million, plus any applicable False Claims Act multiplier and penalties; 

  
 19 

	 	iii.	 if any payments are avoided and recovered by Mallinckrodt, a receiver, trustee, custodian, or similar official
for Mallinckrodt, Relators shall, within thirty days of written notice from the United States to the undersigned Relators’ counsel, return any portions of such payments already paid by the United States to Relators pursuant to Paragraph 2;

  

	 	iv.	 Mallinckrodt shall not argue or otherwise contend in a Future Insolvency Proceeding that the United
States’ claim, action, or proceeding in respect of the matters covered by this Settlement Agreement is subject to an automatic stay and, to the extent necessary, consents to relief from the automatic stay for cause under 11 U.S.C. §
362(d)(1). Mallinckrodt waives and shall not plead, argue, or otherwise raise any defenses under the theories of statute of limitations, laches, estoppel, or similar theories, including theories related to the Bankruptcy Proceedings such as
discharge, to any such civil or administrative claim, action, or proceeding brought by the United States within 120 days of written notification to Mallinckrodt that the releases have been rescinded pursuant to this Paragraph, except to the extent
such defenses were available on January 20, 2012; and 

  
 20 

	 	v.	 OIG-HHS may exclude Mallinckrodt from participating in all Federal
health care programs until Mallinckrodt cures the default and/or pays the unpaid portion of the Settlement Amount, interest due, and collection costs. OIG-HHS will provide written notice of any such exclusion
to Mallinckrodt. Mallinckrodt waives any further notice of the exclusion under 42 U.S.C. § 1320a-7(b)(7), and agrees not to contest such exclusion either administratively or in any state or federal court.
Reinstatement to program participation is not automatic. If at the end of the period of exclusion Mallinckrodt wishes to apply for reinstatement, Mallinckrodt must submit a written request for reinstatement to
OIG-HHS in accordance with the provisions of 42 C.F.R. §§ 1001.3001-.3005. Mallinckrodt will not be reinstated unless and until the OIG approves such request for reinstatement. The option for
exclusion for default as described in this Paragraph is in addition to, and not in lieu of, the options identified in this Agreement or otherwise available. 

f. Mallinckrodt’s obligations under this Agreement may not be avoided pursuant to 11 U.S.C. § 547 or 11 U.S.C. § 548(a)(1), and
Mallinckrodt shall not argue or otherwise take the position in any Future Insolvency Proceeding or in any other case, proceeding, or action that: (i) Mallinckrodt’s obligations under this Agreement may be avoided under 11 U.S.C. §
547; (ii) the mutual promises, covenants, and obligations set forth in this Agreement do not constitute a contemporaneous exchange for new value given to Mallinckrodt; or (iii) the mutual promises, covenants, and obligations set forth herein
are not intended to and do not, in fact, represent a reasonably equivalent exchange of value or that such mutual promises, covenants and obligations are intended to hinder, delay, or defraud any entity to which Mallinckrodt was or became indebted to
on or after the date of this Agreement, within the meaning of 11 U.S.C. § 548(a)(1). 

  
 21 

 21. In evaluating whether to execute this Agreement, the Parties warrant that the mutual
promises, covenants, and obligations set forth herein constitute a contemporaneous exchange for new value given to Mallinckrodt, within the meaning of 11 U.S.C. § 547(c)(1), and the Parties conclude that these mutual promises, covenants, and
obligations do, in fact, constitute such a contemporaneous exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set forth herein are intended to and do, in fact, represent a reasonably equivalent exchange of
value that is not intended to hinder, delay, or defraud any entity to which Mallinckrodt was or became indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1). 

22. Upon receipt of the First Installment Payment described in Paragraph 1, above, and Exhibit B, attached, the Parties shall promptly sign and
file in the Civil Actions a Joint Stipulation of Dismissal pursuant to the terms of this Settlement Agreement of all claims against Mallinckrodt pursuant to Rule 41(a)(1). The Joint Stipulation of Dismissal shall be with prejudice as to the United
States’ and the Relators claims in the Civil Actions against Mallinckrodt as to the Covered Conduct and pursuant to the terms and conditions of this Agreement. 

23. Except as otherwise provided herein, each Party shall bear its own legal and other costs incurred in connection with this matter, including
the preparation and performance of this Agreement. 
 24. Each Party and signatory to this Agreement represents that it freely and
voluntarily enters into this Agreement without any degree of duress or compulsion. 

  
 22 

 25. This Agreement is governed by the laws of the United States. The exclusive venue for any
dispute relating to this Agreement is the United States District Court for the Eastern District of Pennsylvania. For purposes of construing this Agreement, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and
shall not, therefore, be construed against any Party for that reason in any subsequent dispute. 
 26. This Agreement constitutes the
complete agreement between the Parties. This Agreement may not be amended except by written consent of the Parties. Forbearance by the United States from pursuing any remedy or relief available to it under this Agreement shall not constitute a
waiver of rights under this Agreement. 
 27. Nothing herein is intended to, or does, in any manner waive, limit, impair or restrict the
ability of the United States to protect and preserve its rights, remedies and interests, including any other claims against Mallinckrodt or other parties, or its full participation in the Bankruptcy Proceedings. Furthermore, nothing in this
Agreement shall be construed to prohibit the United States from appearing as a party-in-interest in any matter to be adjudicated in the Bankruptcy Proceedings so long as
any appearance by the United States and the positions advocated by the United States in connection therewith are consistent with this Agreement. 

28. In the event of any conflict among the terms and provisions in Definitive Documents, on the one hand, and this Agreement, on the other
hand, the terms and provisions of this Agreement shall control. 
 29. The undersigned counsel represent and warrant that they are fully
authorized to execute this Agreement on behalf of the persons and entities indicated below. 
 30. This Agreement may be executed in
counterparts, each of which constitutes an original and all of which constitute one and the same Agreement. 

  
 23 

 31. This Agreement is binding on Mallinckrodt’s successors, transferees, heirs, and
assigns. 
 32. This Agreement is binding on Relators’ successors, transferees, heirs, and assigns. 

33. All Parties consent to the United States’ disclosure of this Agreement, and information about this Agreement, to the public. 

34. This Agreement is effective on the date of signature of the last signatory to the Agreement (Effective Date of this Agreement). Facsimiles
and electronic transmissions of signatures shall constitute acceptable, binding signatures for purposes of this Agreement. 

  
 24 

 THE UNITED STATES OF AMERICA 

 

							
	DATED: 3/7/2022	 		 	BY:	 	 /s/ Jennifer Arbittier Williams

		 		 		 	JENNIFER ARBITTIER WILLIAMS
		 		 		 	United States Attorney
		 		 		 	Eastern District of Pennsylvania
				
		 		 		 	 /s/ Gregory B. David

		 		 		 	GREGORY B. DAVID
		 		 		 	Chief, Civil Division
				
		 		 		 	 /s/ Charlene K. Fullmer

		 		 		 	CHARLENE K. FULLMER
		 		 		 	Deputy Chief, Civil Division
				
		 		 		 	 /s/ Colin Cherico

		 		 		 	COLIN CHERICO
		 		 		 	PAUL KOOB
		 		 		 	MATTHEW HOWATT
		 		 		 	Assistant United States Attorneys
				
	DATED: 03/07/2022	 		 	BY:	 	 /s/ Augustine Ripa

		 		 		 	AUGUSTINE RIPA
		 		 		 	DANIEL SCHIFFER
		 		 		 	Trial Attorneys
		 		 		 	 Commercial Litigation Branch
 Civil
Division

		 		 		 	United States Department of Justice
				
	DATED:                         	 		 	BY:	 	  

		 		 		 	LISA M. RE
		 		 		 	 Assistant Inspector General for Legal Affairs

Office of Counsel to the Inspector General
 Office of Inspector
General

		 		 		 	United States Department of Health and Human Services

  
 25 

 THE UNITED STATES OF AMERICA 

 

							
	DATED:                     	 		 	BY:	 	
                     
    

		 		 		 	AUGUSTINE RIPA
		 		 		 	DANIEL SCHIFFER
		 		 		 	Trial Attorneys
		 		 		 	Commercial Litigation Branch
		 		 		 	Civil Division
		 		 		 	United States Department of Justice
				
	DATED:                     	 		 	BY:	 	
                     
    

		 		 		 	WILLIAM M. McSWAIN
		 		 		 	United States Attorney
		 		 		 	Eastern District of Pennsylvania
				
		 		 		 	  

		 		 		 	GREGORY B. DAVID
		 		 		 	Chief, Civil Division
				
		 		 		 	  

		 		 		 	CHARLENE K. FULLMER
		 		 		 	Deputy Chief, Civil Division
				
		 		 		 	  

		 		 		 	COLIN CHERICO
		 		 		 	PAUL KOOB
		 		 		 	MATTHEW HOWATT
		 		 		 	Assistant United States Attorneys
				
	DATED: 02/07/2022	 		 	BY:	 	 /s/ Lisa M. Re

		 		 		 	LISA M. RE
		 		 		 	 Assistant Inspector General for Legal Affairs

Office of Counsel to the Inspector General
 Office of Inspector
General

		 		 		 	United States Department of Health and Human Services

  
 26 

 MALLINCKRODT ARD, LLC - DEFENDANT 

							
				
	DATED: 03/03/2022	 		 	BY:	 	 /s/ Mark Casey

		 		 		 	MARK CASEY
		 		 		 	Executive Vice President & Chief Legal Officer
				
	DATED: March 3, 2022	 		 	BY:	 	 /s/ Bradley Klein

		 		 		 	BRADLEY KLEIN
		 		 		 	AVIA DUNN
		 		 		 	 Skadden Arps Slate Meagher & Flom LLP

Counsel for Mallinckrodt ARD, LLC

  
 27 

 MALLINCKRODT PLC 

							
				
	DATED: 03/03/2022	 		 	BY:	 	 /s/ Mark Casey

		 		 		 	MARK CASEY
		 		 		 	Executive Vice President & Chief Legal Officer
				
	DATED: March 3, 2022	 		 	BY:	 	 /s/ Bradley A. Klein

		 		 		 	BRADLEY KLEIN
		 		 		 	AVIA DUNN
		 		 		 	Skadden Arps Slate Meagher & Flom LLP
		 		 		 	Counsel for Mallinckrodt PLC

  
 28 

 CHARLES STRUNCK – RELATOR 

							
				
	DATED: 2/7/2022	 		 	BY:	 	 /s/ Charles Strunck

		 		 		 	CHARLES STRUNCK
				
	DATED: 2/7/2022	 		 	BY:	 	 /s/ Ross Begelman

		 		 		 	ROSS BEGELMAN
		 		 		 	Begelman & Orlow, P.C.
		 		 		 	Counsel for Strunck

  
 29 

 LISA PRATTA – RELATOR 

							
				
	DATED: 2/4/2022	 		 	BY:	 	 /s/ Lisa Pratta

		 		 		 	LISA PRATTA
				
	DATED: 2/4/2022	 		 	BY:	 	 /s/ Ross Begelman

		 		 		 	ROSS BEGELMAN
		 		 		 	Begelman & Orlow, P.C.
		 		 		 	Counsel for Pratta

  
 30 

 SCOTT CLARK – RELATOR 

							
				
	DATED: 3-3-22	 		 	BY:	 	 /s/ Andrew Scott Clark

		 		 		 	SCOTT CLARK
				
	DATED: 3/3/22	 		 	BY:	 	 /s/ Brian J. McCormick, Jr.

		 		 		 	BRIAN J. McCORMICK, Jr.
		 		 		 	Ross Feller Casey, LLP
		 		 		 	Counsel for Clark
				
	DATED: 3/3/2022	 		 	BY:	 	 /s/ Jennifer J. Middleton

		 		 		 	JENNIFER J. MIDDLETON
		 		 		 	Johnson Johnson Lucas & Middleton, PC
		 		 		 	Counsel for Clark

  
 31 

 EXHIBIT A: CERTAIN DEFINITIONS 

As used in this Agreement, the following terms have the following meanings: 
  

	 	a.	 “Approved Plan” means a plan of reorganization for Mallinckrodt that is
consistent in all material respects with this Agreement. 

  

	 	b.	 “Approved Plan Effective Date” means the date on which the Approved Plan
becomes effective in accordance with its terms. 

  

	 	c.	 “Definitive Documents” means all material agreements, schedules and
Bankruptcy Court or other judicial or regulatory orders that are necessary to implement this Settlement Agreement, including the Confirmation Order and the Approved Plan. 

 

	 	d.	 “Scheme of Arrangement” means the scheme of arrangement based on the Plan to
be submitted for approval in the Examinership Proceeding. 

 Exhibit B – Installment Payment Schedule 

Mallinckrodt will pay the Settlement Amount to the United States in eight installments as follows: 

 

	 	a.	 $1,516,853.93, plus interest on the full unpaid amount, upon the Approved Plan Effective Date in the Chapter 11
Cases contemplated in recital I of this Agreement (“First Installment Payment”); 

  

	 	b.	 $1,516,853.93, plus interest on the full unpaid amount, shall be due within one year of the First Installment
Payment; 

  

	 	c.	 $2,022,471.91, plus interest on the full unpaid amount, shall be due within two years of the First Installment
Payment; 

  

	 	d.	 $2,022,471.91, plus interest on the full unpaid amount, shall be due within three years of the First
Installment Payment; 

  

	 	e.	 $3,286,516.85, plus interest on the full unpaid amount shall be due within four years of the First Installment
Payment; 

  

	 	f.	 $3,286,516.85, plus interest on the full unpaid amount shall be due within five years of the First Installment
Payment; 

  

	 	g.	 $6,320,224.72, plus interest on the full unpaid amount shall be due within six years of the First Installment
Payment; 

  

	 	h.	 $6,320,224.72, plus interest on the full unpaid amount shall be due within seven years of the First Installment
Payment. 

  
 33Document

Exhibit 4.1
 
DESCRIPTION OF REGISTERED SECURITIES
 
LiveVox Holdings, Inc. (“we,” “us,” “our,” or the “Company”) has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Class A common stock, par value $0.0001 per share (“Common Stock”), redeemable warrants, each whole warrant exercisable to purchase one share of Common Stock at an exercise price of $11.50 (the “Warrants”), and units, each consisting of one share of Common Stock and one-half of one redeemable Warrant (the “Units”). The following summary of the material terms of the Company’s securities is not intended to be a complete summary of the rights and preferences of such securities. We urge you to read our Second Amended and Restated Certificate of Incorporation (our “Certificate of Incorporation”) in its entirety for a complete description of the rights and preferences of Company’s securities.
 
Defined terms used herein and not defined herein shall have the meaning ascribed to such terms in the Company’s Annual Report on Form 10-K to which this Description of Securities is attached as an exhibit.

Authorized and Outstanding Stock
The Company’s Certificate of Incorporation authorizes the issuance of: (a) 500,000,000 shares of Common Stock and (b) 25,000,000 shares of preferred stock, par value $0.0001 per share.
Common Stock
Voting Power
Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, under the Company’s Certificate of Incorporation, the holders of Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action and are entitled, or will be entitled, as applicable, to one vote per share on matters to be voted on by stockholders. The holders of Common Stock shall at all times vote together as one class on all matters submitted to a vote of the holders of Common Stock under the Company’s Certificate of Incorporation.
Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, under the Company’s Certificate of Incorporation, the holders of Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action and are entitled, or will be entitled, as applicable, to one vote per share on matters to be voted on by stockholders.
Dividends
Subject to the rights, if any, of the holders of any outstanding shares of preferred stock, under the Company’s Certificate of Incorporation, holders of Common Stock will be entitled to receive such dividends and other distributions, if any, as may be declared from time to time by our board of directors (our “Board”) in its discretion out of funds legally available therefor and shall share equally on a per share basis in such dividends and distributions. We have not paid any cash dividends on our Common Stock to date. In addition, our Board is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.
Liquidation, Dissolution and Winding Up
In the event of the voluntary or involuntary liquidation, dissolution or winding-up of the Company under the Company’s Certificate of Incorporation, the holders of Common Stock will be entitled to receive all the remaining assets of the Company available for distribution to stockholders, ratably in proportion to the number of shares of Common Stock held by them, after the rights of the holders of the preferred stock have been satisfied.
Preemptive or Other Rights
Under the Company’s Certificate of Incorporation, our stockholders have no preemptive or other subscription rights, and there are no sinking fund or redemption provisions applicable to our Common Stock.
Election of Directors
1

Our Board is currently divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term.
Under the terms of the Company’s Certificate of Incorporation, the term of the Class I directors in place at such time will expire at the 2022 annual meeting of the stockholders of the Company; the term of the Class II directors in place at such time will expire at the 2023 annual meeting of the stockholders of the Company; and the term of the Class III directors in place at such time will expire at the 2024 annual meeting of the stockholders of the Company.
Under the Company’s Certificate of Incorporation, there is no cumulative voting with respect to the election of directors, with the result that directors will be elected by a plurality of the votes cast at a meeting of stockholders by holders of our Common Stock.
Preferred Stock
Our Certificate of Incorporation provides that shares of preferred stock may be issued from time to time in one or more series. Our Board is authorized to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights, if any, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the Common Stock and could have anti-takeover effects. The ability of our Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future.
Warrants
Public Warrants
Following the Merger, there were 13,333,328 Warrants to purchase Common Stock outstanding, consisting of 12,499,995 Public Warrants and 833,333 Forward Purchase Warrants (collectively, “Warrants”). Each Warrant entitles the registered holder to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as discussed below at any time. The Warrants will expire on June 18, 2026 at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
We are not obligated to deliver any shares of Common Stock pursuant to the exercise of a Warrant and will have no obligation to settle such Warrant’s exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the Warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No Warrant will be exercisable for cash or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant will not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless. In the event that a registration statement is not effective for the exercised Warrants, the purchaser of a Unit containing such Warrant will have paid the full purchase price for the Unit solely for the share of Common Stock underlying such Unit.
We have agreed we will use our best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants. We will use our best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Warrants in accordance with the provisions of the Warrant Agreement between Continental Stock Transfer & Trust Company, as Warrant Agent, and us. Notwithstanding the above, if our Common Stock is at the time of any exercise of a Warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of Public Warrants who exercise their Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but will use our best efforts to register the shares under applicable blue sky laws to the extent an exemption is not available.
We may call the Warrants for redemption:
 
												
	 	•	 	in whole and not in part;

 
												
	 	•	 	at a price of $0.01 per Warrant;

 
2

												
	 	•	 	upon not less than 30 days’ prior written notice of redemption to each Warrant holder; and

 
												
	 	•	 	if, and only if, the last reported sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date we send the notice of redemption to the warrantholders.

If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
We have established the last criterion of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Warrants, each Warrant holder will be entitled to exercise his, her or its Warrant prior to the scheduled redemption date. However, the price of the Common Stock may fall below the $18.00 redemption trigger price as well as the $11.50 Warrant exercise price after the redemption notice is issued.
If we call the Warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise his, her or its Warrant to do so on a “cashless basis.” In determining whether to require all holders to exercise their Warrants on a “cashless basis,” our management will consider, among other factors, our cash position, the number of Warrants that are outstanding and the dilutive effect on our stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our Warrants. If our management takes advantage of this option, all warrantholders would pay the exercise price by surrendering their Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the difference between the exercise price of the Warrants and the fair market value (defined below) by (y) the fair market value. The fair market value shall mean the average reported last sale price of the Common Stock for the ten trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the warrant holders. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Common Stock to be received upon exercise of the Warrants, including the fair market value in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a Warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the Warrants after our initial business combination.
A holder of a Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the shares of Common Stock outstanding immediately after giving effect to such exercise.
If the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise of each Warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering to holders of Common Stock entitling holders to purchase shares of Common Stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Common Stock) multiplied by (ii) one minus the quotient of (x) the price per share of Common Stock paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in determining the price payable for Common Stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of Common Stock as reported during the ten trading day period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.
In addition, if we, at any time while the Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Common Stock on account of such shares of Common Stock (or other shares of our capital stock into which the Warrants are convertible), other than (a) as described above, or (b) certain ordinary cash dividends, then the Warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Common Stock in respect of such event.
If the number of outstanding shares of our Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of 
3

Common Stock issuable on exercise of each Warrant will be decreased in proportion to such decrease in outstanding shares of Common Stock.
Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as described above, the Warrant exercise price will be adjusted by multiplying the Warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.
In case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the warrantholders will thereafter have the right to purchase and receive, upon the basis of and upon the terms and conditions specified in the Warrants and in lieu of the shares of our Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the warrantholder would have received if such holder had exercised their Warrants immediately prior to such event. However, if such holders were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets for which each Warrant will become exercisable will be deemed to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively make such election, and if a tender, exchange or redemption offer has been made to and accepted by such holders under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than 50% of the outstanding shares of Common Stock, the holder of a Warrant will be entitled to receive the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in the Warrant Agreement. Additionally, if less than 70% of the consideration receivable by the holders of Common Stock in such a transaction is payable in the form of Common Stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Warrant properly exercises the Warrant within 30 days following public disclosure of such transaction, the Warrant exercise price will be reduced as specified in the Warrant Agreement based on the per share consideration minus the Black-Scholes Warrant Value (as defined in the Warrant Agreement) of the Warrant.
The Warrants have been issued in registered form under a Warrant Agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. You should review a copy of the Warrant Agreement, which is filed as Exhibit 4.2 to our Annual Report on Form 10-K to which this Description of Securities is attached as an exhibit, for a complete description of the terms and conditions applicable to the Warrants. The Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants.
The Warrants may be exercised upon surrender of the Warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the Warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Warrants being exercised. The warrantholders do not have the rights or privileges of holders of Common Stock and any voting rights until they exercise their Warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.
Warrants may be exercised only for a whole number of shares of Common Stock. No fractional shares will be issued upon exercise of the Warrants. If, upon exercise of the Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to the warrantholder.

4

Forward Purchase Warrants
The Forward Purchase Warrants are non-redeemable and exercisable on a cashless basis so long as they are held by CFI Sponsor LLC (the “Sponsor”) or its permitted transferees. The Forward Purchase Warrants have terms and provisions that are identical to those of the Public Warrants. If the Forward Purchase Warrants are held by holders other than the Sponsor or its permitted transferees, the Forward Purchase Warrants are redeemable by us and exercisable by the holders on the same basis as the Public Warrants.
If holders of the Forward Purchase Warrants elect to exercise them on a cashless basis, they will pay the exercise price by surrendering their Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the difference between the exercise price of the Warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Common Stock for the ten trading days ending on the third trading day prior to the date on which the notice of Warrant exercise is sent to the warrant agent. The reason that we agreed that these Warrants will be exercisable on a cashless basis so long as they are held by the Sponsor and permitted transferees is because it was not known at the time of the Sponsor's purchase of the Forward Purchase Warrants whether they would be affiliated with us following a business combination. If they remained affiliated with us, their ability to sell our securities in the open market would have been be significantly limited. We have policies in place that prohibit insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders are permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of material non-public information. Accordingly, unlike public stockholders who could exercise their Warrants and sell the shares of Common Stock received upon such exercise freely in the open market in order to recoup the cost of such exercise, insiders could be significantly restricted from selling such securities. As a result, we believed that allowing the holders to exercise such Warrants on a cashless basis is appropriate.
Transfer Agent and Warrant Agent
The transfer agent for our Common Stock and warrant agent for our Warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust Company in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all liabilities, including judgments, costs and reasonable counsel fees that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity.
Certain Anti-Takeover Provisions of Delaware Law, the Company’s Certificate of Incorporation and Bylaws
Provisions of the DGCL and the Company’s Certificate of Incorporation could make it more difficult to acquire the Company by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of the Company to first negotiate with the board of directors. We believe that the benefits of these provisions outweigh the disadvantages of discouraging certain takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms and enhance the ability of our board of directors to maximize stockholder value. However, these provisions may delay, deter or prevent a merger or acquisition of us that a stockholder might consider is in its best interest, including those attempts that might result in a premium over the prevailing market price of the Common Stock.
Our Certificate of Incorporation provides for certain other provisions that may have an anti-takeover effect:
 
												
	 	•	 	There is no cumulative voting with respect to the election of directors.

 
												
	 	•	 	Our Board is empowered to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death, or removal of a director in certain circumstances.

 
												
	 	•	 	Directors may only be removed from the Board for cause.

 
												
	 	•	 	There is a prohibition on stockholders calling a special meeting and a requirement that a meeting of stockholders may only be called by members of our Board, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors.

 
5

												
	 	•	 	Our authorized but unissued Common Stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

We have elected not to be governed by Section 203 of the DGCL. Notwithstanding the foregoing, the Company’s Certificate of Incorporation provides that we will not engage in any “business combinations” (as defined in the Company’s Certificate of Incorporation), at any point in time at which our Common Stock is registered under Section 12(b) or 12(g) of the Exchange Act, with any “interested stockholder” (as defined in the Company’s Certificate of Incorporation) for a three-year period after the time that such person became an interested stockholder unless:
 
												
	 	•	 	prior to such time, the Board approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 
												
	 	•	 	upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the Company outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

  
												
	 	•	 	at or subsequent to such time, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock of the Company which is not owned by the interested stockholder

Forum Selection Clause
Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1) derivative action or proceeding brought on behalf of the Company, (2) action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or employee of the Company to the Company or its stockholders, (3) action asserting a claim pursuant to any provision of the DGCL or the Company’s Certificate of Incorporation or our Amended and Restated Bylaws, or (4) action asserting a claim against the Company, its directors, officers or employees governed by the internal affairs doctrine. Notwithstanding the foregoing, our Certificate of Incorporation provides that the provision described in the preceding paragraph shall not apply to suits to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our Certificate of Incorporation further provides the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our decision to adopt a federal forum provision for suits arising under federal securities laws in our Certificate of Incorporation followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. However, such provision may not be enforceable under Section 22 of the Securities Act, and it may be possible for the Company to be sued in applicable state and local courts notwithstanding such provision.
Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.
6

Registration Rights
The Company entered into the Amended and Restated Registration Rights Agreement with the Sponsor and certain other stockholders of the Company, including the LiveVox Stockholder. Pursuant to the terms of the Amended and Restated Registration Rights Agreement, (a) any outstanding share of Common Stock or any other equity security of the Company held by a signatory thereto (besides the Company) as of the date of the Amended and Restated Registration Rights Agreement or thereafter acquired by a such holder and (b) any other equity security of the Company issued or issuable with respect to any such share of Common Stock held by such holder by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise, will be entitled to registration rights.
The Amended and Restated Registration Rights Agreement provides that the Company will, as soon as practicable, but in any event within 30 days after the consummation of the Merger, file with the SEC a shelf registration statement. Such shelf registration statement shall register the resale of all securities registrable pursuant to the Amended and Restated Registration Rights Agreement held by the signatories thereto (besides the Company) from time to time, and the Company will use commercially reasonable efforts to have such registration statement declared effective as soon as practicable after the filing thereof, but in no event later than 60 days following the initial filing deadline. A majority of the signatories to the Amended and Restated Registration Rights Agreement associated with the Sponsor, as a group and the LiveVox Stockholder are each entitled to demand that the Company register shares of Common Stock held by such parties. The signatories affiliated with the Sponsor are entitled to make up to three such demands and the LiveVox Stockholder is entitled to make unlimited demands. In addition, the Amended and Restated Registration Rights Agreement provides certain “piggy-back” registration rights. The Company will bear the expenses incurred in connection with the filing of any registration statements pursuant to the terms of the Amended and Restated Registration Rights Agreement. The Company and the other signatories to the Amended and Restated Registration Rights Agreement will provide customary indemnification in connection with offerings of Common Stock effected pursuant to the terms of the Amended and Restated Registration Rights Agreement.
Listing of Securities
Our Common Stock, Units and Public Warrants are listed on Nasdaq under the symbols “LVOX,” “LVOXU” and “LVOXW,” respectively.

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]